Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TLR2 | O60603 | 4/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758276 | 0.92 | KMT2A (0.67) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL22367804 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL20450573 | 0.88 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450603 | 0.88 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450575 | 0.88 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450605 | 0.88 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL18571525 | 0.88 | TLR2 (0.56) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL18571434 | 0.88 | TLR2 (0.56) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL15387319 | 0.88 | TLR2 (0.60) | KMT2ATLR2TLR1MDM2SIRT2 | |
| SCHEMBL15387434 | 0.88 | TLR2 (0.60) | KMT2ATLR2TLR1MDM2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | KMT2A 868/4885TLR2 2343/4885TLR1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.